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Abstract
Background: The elimination of blinding trachoma focuses on controlling Chlamydia trachomatis infection through mass
antibiotic treatment and measures to limit transmission. As the prevalence of disease declines, uncertainty increases over
the most effective strategy for treatment. There are little long-term data on the effect of treatment on infection, especially in
low prevalence settings, on which to base guidelines.
Methodology/Principal Findings: The population of a cluster of 14 Gambian villages with endemic trachoma was examined
on seven occasions over five years (baseline, 2, 6, 12, 17, 30 and 60 months). Mass antibiotic treatment was given at baseline
only. All families had accessible clean water all year round. New latrines were installed in each household after 17 months.
Conjunctival swab samples were collected and tested for C. trachomatis by PCR. Before treatment the village-level
prevalence of follicular trachoma in 1 to 9 year olds (TF%1–9) was 15.4% and C. trachomatis was 9.7%. Antibiotic treatment
coverage was 83% of the population. In 12 villages all baseline infection cleared and few sporadic cases were detected
during the following five years. In the other two villages treatment was followed by increased infection at two months,
which was associated with extensive contact with other untreated communities. The prevalence of infection subsequently
dropped to 0% in these 2 villages and 0.6% for the whole population by the end of the study in the absence of any further
antibiotic treatment. However, several villages had a TF%1–9 of .10%, the threshold for initiating or continuing mass
antibiotic treatment, in the absence of any detectable C. trachomatis.
Conclusions/Significance: A single round of mass antibiotic treatment may be sufficient in low prevalence settings to
control C. trachomatis infection when combined with environmental conditions, which suppress transmission, such as a
good water supply and sanitation.
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Introduction
Trachoma is the leading infectious cause of blindness worldwide
[1]. Repeated infection of the ocular surface by Chlamydia
trachomatis, provokes conjunctival inflammation (active trachoma)
and scarring. This may progress in some people to entropion (in-
turned eyelid), trichiasis (TT, lashes scratching the cornea) and
blinding corneal opacification. The World Health Organization’s
(WHO) most recent estimates indicate approximately 40 million
people have active trachoma, 8 million have un-operated trichiasis
and 1.3 million are blind [1,2]. The burden of this disease falls
disproportionately on poor rural communities, predominantly in
Sub-Saharan Africa. In a major WHO-led effort to control
trachoma, the Alliance for the Global Elimination of Blinding
Trachoma by 2020 (GET2020) was formed which focuses on the
development and implementation of the SAFE Strategy: Surgery
for trichiasis, Antibiotics for infection, Facial cleanliness, and
Environmental improvements to suppress transmission [3].
Trachoma was endemic in many parts of Europe in the 19
th
century; however, it gradually declined in the absence of any
trachoma-specific interventions such as antibiotic treatment. This
was attributed to general improvements in living conditions and
hygiene, and underlines their importance in controlling trachoma.
Unfortunately, such socio-economic transformation is only
arriving slowly in many of today’s trachoma endemic regions.
Through implementing control programmes some encouraging
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a marked decline [4]. Outside Sub-Saharan Africa, Morocco,
Iran, Oman and Mexico have reported elimination of blinding
trachoma. However, other countries have yet to experience similar
reductions, probably because of higher initial levels of disease and
variations in environmental factors such as water availability [2].
Typically, control programmes rely on the clinical signs of
active trachoma to determine whether treatment should be given
or stopped. Unfortunately, there is often a mismatch between
disease and infection: infection may detected without clinical
disease and disease may be found without infection. The
correlation between disease and infection is not particularly strong
and tends to weaken as the community prevalence drops [5,6].
This led the WHO to recommend the use of mass drug
administration (MDA) with either single –dose oral azithromycin
(which has therapeutic tissue concentrations for several days) or
topical tetracycline to entire communities or districts [7]. Revised
recommendations were published in 2004 with emphasis placed
on the prevalence of follicular trachoma in children aged 1–9 years
(TF%1–9) as the primary clinical indicator [8]. Where TF%1–9
exceeds 10%, three annual MDAs followed by re-assessment, to
determine whether to continue treating, is recommended [8]. This
strategy increases the chance that infected persons are treated.
However, in low prevalence settings where infection and disease
are poorly correlated it may not represent the most efficient way to
eliminate trachoma. The WHO also published specific Ultimate
Intervention Goals (UIG); targets that need to be reached for the
national certification of elimination of blinding trachoma [8]. For
the surgery component of the SAFE strategy the UIG is to bring
the population prevalence of TT below 0.1% in people aged 15
years and over. For the ‘‘AFE’’ components the UIG is to bring
TF%1–9 below 5%. At this level it is expected that C. trachomatis
infection will be too infrequent to drive scarring, although, there
are no published data demonstrating this.
The efficient and timely elimination of blinding trachoma is a
major challenge for prevention of blindness programmes. It
presents various practical difficulties, which need to be overcome
if, for example, regular high coverage with antibiotic treatment is
to be achieved. In addition, there are significant areas where the
evidence base which guides policy, particularly around the use of
antibiotic treatment, needs to be strengthened. In particular, there
are limited published long-term data from low prevalence settings
on C. trachomatis infection and disease to inform policy makers and
programme managers in the development of guidelines for
handling the end stage of trachoma elimination. Several key
questions need to be answered in a range of endemic settings. Who
should be treated? How often should treatment be given? What
indicators can be used to guide the treatment decision? When can
treatment be discontinued? What form of surveillance is needed
after discontinuing treatment? What environmental changes
reinforce the reduction achieved by antibiotic?
We investigated the long-term effect of a single MDA on both
the signs of trachoma and ocular C. trachomatis infection in a low
prevalence setting in The Gambia. Other components of the
SAFE strategy were also implemented, without any additional
antibiotic treatment. Here we present results to five years; the first
17 months have previously been reported [9].
Methods
Ethical permission
Approval for this study was given by the Gambian Govern-
ment/Medical Research Council Joint Ethics Committee (SCC
Number: 856) and by the London School of Hygiene & Tropical
Medicine Ethics Committee. Informed consent at village, family
and individual level was required before enrolment.
Study area and population
A rapid assessment of active trachoma in children was
conducted in 31 villages in Upper and Lower Saloum Districts,
The Gambia. A geographically defined study area was selected,
which contained a group of communities with endemic trachoma.
This cluster of villages was chosen as it was typical of rural
Gambia, where there is marked variation in the prevalence of
active disease between neighbouring communities. The study area
population was enumerated and information was collected on
latrine access, water supply, livestock, house construction and
other socio-economic indicators. Individuals normally resident in
the study area for at least 6 months of the year were enrolled.
Visitors were excluded. New residents were included in the study
population if they lived in the study area for at least six months.
For the first 17 months of this study each household was visited
weekly by a project fieldworker to update the census. Inward and
outward travel was recorded. Episodes of illness and the treatment,
especially antibiotics, were also recorded. The weekly visits
stopped after the first 17 months. The census was updated again
just prior to the 30 and 60-months follow-ups. At five years
household access to a functional pit latrine was reassessed.
Clinical assessment
The study population was assessed on seven occasions over five
years: baseline (April 2001), 2, 6, 12, 17, 30 and 60 months. The
previously reported 6 and 12 month data are not presented here
[9]. On each occasion all individuals normally resident within the
study area were eligible for assessment. The assessments were
conducted within a 6 to 10 day period. Individuals who had
travelled out of the study area for this period were not seen. All
clinical observations were made by the same ophthalmologist.
Faces were assessed for fly-eye contact and the presence of nasal
and ocular discharge. The left eye of each subject was examined
for trachoma and classified using the WHO Trachoma Grading
System [10]. Clinically active trachoma was defined as the
Author Summary
Trachoma is the most common infectious cause of blindness
worldwide. Mass antibiotic treatment with azithromycin is
used to control ocular Chlamydia trachomatis infection.
There is uncertainty over how frequently and for how
long treatment is needed, particularly in low prevalence
settings. This study examines the effect of a single round
of treatment on clinical disease and infection in a cluster
of trachoma endemic Gambian villages over a five-year
period. These villages had good water supplies and
sanitation improved part way through the study. We
found treatment was followed by a marked decline in
infection prevalence (by PCR) to less than 1%. The de-
cline in prevalence of active disease in children was
less marked. Several villages had a prevalence of active
trachoma in 1 to 9 year old children of greater than 10%
during the follow-up period, mostly in the absence of
detectable infection. The implication of this study is that
a single, high coverage mass treatment may be sufficient
to control C. trachomatis infection in a low prevalence
setting, particularly when combined with environmental
measures to limit transmission. However, relying on
clinical signs to guide treatment decisions is likely to lead
to significant amounts of over treatment where current
guidelines are implemented.
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score of 3 (P3), equivalent to Trachomatous Inflammation,
Follicular (TF) and Trachomatous Inflammation, Intense (TI) of
the WHO Simplified Trachoma Grading System, respectively
[11]. A Dacron swab sample was collected from the left upper
tarsal conjunctiva, in a standardised manner, for the detection of
C. trachomatis [9]. Care was taken to minimise the risk of
contamination, by carefully handling only the far end of the swab
(away from the Dacron head) and washing of the examiner’s hands
between subjects. All samples were kept on ice packs until transfer
to a 220uC freezer later the same day for storage until processing.
Antibiotic treatment
Mass antibiotic treatment of the entire population of the study
area was conducted by the study team immediately after the
baseline clinical assessment in April 2001. Children (,16 years)
were offered a single oral dose of Azithromycin (suspension,
20mg/kg, up to a maximum of 1g). Infants under six months were
given tetracycline eye ointment (1%, twice daily for six weeks).
Adults were treated with a single oral dose of Azithromycin
(tablets, 1g), except for women of childbearing age who received
oral erythromycin, as per the Gambian National Treatment
Guidelines at that time (500mg, twice daily for two weeks). During
the follow-up period no further treatment was given for active
trachoma by the study team or the National Eye Care Programme
(NECP). The final five year follow-up took place after the
introduction of the current WHO trachoma treatment guidelines,
therefore, at the end of the study all villages with a TF%1–9 of 10%
or more received mass antibiotic treatment as outlined above [8].
Other trachoma control measures
All individuals with trachomatous trichiasis were offered
surgery, which was provided free of charge within the community.
After the 17-month follow-up new concrete pit latrines were
installed in each household. The project team provided health
education about trachoma to the communities involved through-
out the course of the study.
Detection of C. trachomatis
C. trachomatis was detected using the Amplicor CT/NG kit
(Roche Molecular Systems, Branchburg, NJ). For samples in
which C. trachomatis was detected by Amplicor, the infection load
was estimated by quantitative real-time PCR of the C. trachomatis
ompA gene using a previously described methodology [12]. The
quantitative PCR method used was based on the ompA gene
sequence of C. trachomatis serovar A (Forward Primer: 59-
GCTGTGGTTGAGCTTTATACAGACAC-39, Reverse Prim-
er: 59-TTTAGGTTTAGATTGAGCATATTGGA-39). For the
30 and 60 month ompA quantitation an additional forward primer
(59-TCTGTTGTTGAGTTGTATACAGATAC-39) was used
which was optimised for estimating serovar B. Quantitation was
done on two 4 mL replicate samples, first with the serovar A
forward primer and then with that for serovar B.
Data analysis
Here we focus on the prevalence of TF and C. trachomatis
infection in 1 to 9 year olds due to the importance placed on this
group in the WHO guidelines [8]. Because of the duration of this
study, many of those who were initially in the 1 to 9 year old group
were above this range by the end. As the probability of being
infected is strongly influenced by age, it is necessary to compare
the same age group rather than the same individuals over the
duration of the study. Hence data were analysed according to each
person’s contemporaneous age at the different study time points;
e.g. we compared all children aged 1 to 9 years at baseline with all
those who were aged 1 to 9 years at five years. The estimated
number of copies of ompA/swab was the geometric mean of two
replicate assays. If infection was detected by Amplicor but no ompA
could be detected by quantitative PCR, a maximum likelihood
copy number estimate was made [12]. Where no C. trachomatis was
detected a copy number of zero was assigned. The estimated copy
numbers in individual samples were combined into an estimate of
the burden of chlamydia infection for the study population as a
whole [13]. An adjusted geometric mean (the Williams Mean) was
calculated by adding 1 copy/swab to each estimated ompA copy
number, calculating the geometric mean and then subtracting 1
copy/swab from the result. This measure can be used where one
or more zero data values make the true geometric mean zero. To
compare the prevalence of TF%1–9 and infection at the final five
year follow-up with those at baseline, the within-village differences
in prevalence were bootstrapped with 100,000 replicates [14]. For
this last analysis, villages were given equal weight irrespective of
numbers sampled. However, results based on minimum variance
weights, taking into account both numbers sampled and intra-
village correlation, were identical at the number of decimals places
used [15]. Data were analysed in STATA version 10 and R
version 2.
Results
Study population
The study population was comprised of all the individuals living
in a geographically defined area 3km by 4km in size in Upper
Saloum District, The Gambia. This area contains a cluster of 14
small villages, which have previously been described in detail [6,9].
At baseline in April 2001 the study area had a total recorded
population of 1595 people. The median age was 14.2 years
(Interquartile range: 6.2–30.2 years) and there were 542 children
aged 1 to 9 years. The mean village size at baseline was 115
people; the individual village population sizes are shown in
Table 1. One village (No. 12) of 123 people withdrew from the
study after the 17-month follow-up. During the course of the five
years we recorded 400 births, 57 deaths, 405 new residents, and
567 people moving away. At five years the total population of the
study area (excluding village 12) had risen slightly to 1667 people.
The age structure was comparable: median age 13.5 years
(Interquartile range 5.5–30.5 years).
The villages in the study area are typical of rural Gambia: the
family compounds are grouped closely together and surrounded
by farmland. The main employment is subsistence farming. All the
households in the study area had access to clean water all year
round within a few minutes’ walk from wells situated in the middle
of each village. At baseline 683/1595 (42.8%; 95% CI: 40.4–45.2)
of the study population had access to a functional latrine in the
family compound, although this varied considerably from village
to village (Table 2). We have previously reported that at baseline
there was a strong association between C. trachomatis infection and
not having access to a latrine (OR 13.3, p,0.0001) [9]. Therefore,
shortly after the 17-month follow-up visit, new pit latrines were
installed in all 114 households. At five years 1154/1667 (69.2%;
95% CI: 67.0–71.4) of the population had access to a functional
latrine (Table 2).
Antibiotic treatment coverage
These communities had not received any mass antibiotic
treatment for trachoma control prior to this study. Antibiotic
treatment coverage at baseline was 83.3% (95% CI: 81.4–85.1) of
Control of Hypoendemic Trachoma in The Gambia
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year olds: oral azithromycin 1079 (81%), oral erythromycin 226
(17%), topical tetracycline 23 (2%). Coverage by village is shown
in Table 1 for all ages and those aged 1 to 9 years at baseline.
Follow-up assessments
The follow-up rates of the 1 to 9 year old children were around
90%; individual village rates at each visit are shown in Table 3.
During the first 17 months of the study 153 episodes of illness were
recorded. Forty-five of these episodes involved treatment with
systemic antibiotics, which were usually obtained from the district
health centre 10km away. This was equivalent to 20 antibiotic
treatments/1000 people/year, during that 17 month period. Co-
trimoxazole (Septrin) was the commonest antibiotic used (61%)
and tetracyclines the next commonest (16%).
Clinical findings
At baseline, the village-level average TF%1–9 was 15.4%
(Table 4). There were marked differences in TF%1–9 between
villages, ranging from 0% (in four) to 46%. It was greater than
10% in seven villages (Table 4). Overall, TF%1–9 declined during
the study: reaching a minimum of 2.6% at 30 months and rising to
4.8% at five years (Figure 1). Comparing the baseline with five
years, the village-level TF%1–9 decreased (in absolute terms,
Table 4) by an average of 9% (95% CI 218 to 22, p=0.002).
Most villages had a reduction in this indicator within the first few
months following MDA (Table 4). In contrast, in villages 1 and 3 it
took longer to decline. By 30 months all villages had 10% TF%1–9
or less. At five years, six villages had cases of TF; two villages had a
TF%1–9 of greater than 10% and were therefore retreated
(Table 4). There was a marked reduction in observed fly-eye
contacts at the time of examination in 1 to 9 year olds from 18.0%
(95% CI 14.7 to 21.5) at baseline to 1.5% (95% CI 0.5–2.5) at 5
years. Similarly there was a large reduction in the proportion of 1
to 9 year olds with unclean faces (nasal or ocular discharge
present): 38.4% (95% CI 34.1 to 42.7) at baseline and 5.0% (95%
CI 3.1 to 6.8) at 5 years.
Trichiasis (TT) was found in 9/592 (1.5%) people 15 years and
over at baseline. Six of these individuals accepted surgery by 12
months. At five years TT was found in 6/456 (1.3%) aged 15 years
and over. Two were incident cases (compared with baseline), three
had TT at baseline (one of which had received surgery) and one
was a new resident at five years.
C. trachomatis infection
Before treatment, the village-level average prevalence of C.
trachomatis infection in 1 to 9 year olds was 9.7% (Table 5). There
was marked variation in prevalence between the study villages
despite their close proximity, with 8 villages having none. There
were 7 villages where the TF%1–9 was greater than 10%, but only
4 of these had any cases of chlamydial infection.
Following MDA the prevalence of C. trachomatis infection
declined gradually, dropping below 1% by five years (Figure 2 &
Table 5). Comparing the baseline with five years, the village-level
prevalence of C. trachomatis infection (in absolute terms, Table 5)
decreased by 10% (95% CI 222 to 21, p=0.001). We have
previously reported the village level heterogeneity in the initial
response to treatment [9]. In most villages (12) all cases of infection
identified before treatment had cleared by two months (Table 5),
and over the subsequent five years we detected only 12 isolated
cases of infection in those villages. In contrast, in villages 1 and 3
the prevalence of infection increased at two months (Table 5). This
increase was strongly associated with the travel of most village
residents to a religious festival in Senegal one month after
receiving treatment, which has been previously reported (OR 12.2,
p,0.0001, 95% CI 4.0–44.1) [9]. After the 2-month assessment,
infection prevalence in these two villages declined progressively to
zero at five years (Table 5). The risk of infection at any follow-up
time point did not differ between those who had received
treatment at baseline and those who had not or who were new
residents during the follow-up (data not shown).
Table 2. Latrine access at baseline and 5 year, by village (all
ages).
Village All ages – Baseline All Ages – 60 Months
Total
Latrine
Access (%) Total
Latrine
Access (%)
1 167 0 (0.0) 213 213 (100.0)
2 109 74 (67.9) 123 123 (100.0)
3 128 12 (9.3) 155 61 (39.3)
4 316 162 (51.3) 358 274 (76.5)
5 142 110 (77.5) 196 88 (44.9)
6 61 0 (0.0) 39 18 (46.2)
7 97 82 (84.5) 107 107 (100.0)
8 99 60 (60.6) 88 64 (72.7)
9 26 26 (100.0) 43 26 (60.5)
10 70 0 (0.0) 112 24 (21.4)
11 119 58 (48.7) 109 94 (86.2)
12 123 77 (62.6) - - -
13 68 18 (26.5) 62 0 (0.0)
14 70 4 (5.7) 62 62 (100.0)
Study Area 1595 683 (42.8) 1667 1154 (69.2)
doi:10.1371/journal.pntd.0000835.t002
Table 1. Baseline village populations and antibiotic
treatment coverage.
Village All ages Children 1–9 years
Total Treated (%) Total Treated (%)
1 167 143 (85.6) 58 50 (86.2)
2 109 98 (89.9) 41 37 (90.2)
3 128 118 (92.2) 48 45 (93.8)
4 316 258 (81.7) 124 114 (91.9)
5 142 107 (75.4) 54 47 (87.0)
6 61 40 (65.6) 15 13 (86.7)
7 97 87 (89.7) 31 31 (100.0)
8 99 83 (83.4) 22 22 (100.0)
9 26 23 (88.5) 5 5 (100.0)
10 70 59 (84.3) 22 21 (95.5)
11 119 98 (82.4) 38 34 (89.5)
12 123 103 (83.7) 39 35 (89.7)
13 68 52 (76.5) 24 21 (87.5)
14 70 59 (84.3) 21 20 (95.2)
Study Area 1595 1328 (83.2) 542 495 (91.3)
doi:10.1371/journal.pntd.0000835.t001
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10% treatment threshold in several villages on one or more
occasions (Table 4). However, in only 4/12 (33%) of these
occasions were cases of chlamydial infection detected in the same
village (Table 5). Conversely, after the two-month follow-up
chlamydial infection was detected in samples from several villages
on one or more occasions (Table 5). However, TF%1–9 exceeded
10% on only 6/16 (37.5%) of these occasions (Table 4).
The geometric mean load of C. trachomatis infection amongst
infected individuals (all ages) increased after treatment
(Table 6). This burden of infection was concentrated in
villages 1 and 3. At 30 and 60 months we found very few
infected individuals, most of whom had low infection loads.
The estimated community C. trachomatis burden (Williams
mean) declined throughout the five-year follow-up period
(Table 6).
Table 3. Follow-up rates for children aged 1 to 9 years at each time point, by village.
Village 2 months 6 months 12 months 17 months 30 months 60 months
% (seen/total) % (seen/total) % (seen/total) % (seen/total) % (seen/total) % (seen/total)
1 80.4 (45/56) 88.7 (55/62) 86.7 (52/60) 81.4 (48/59) 92.5 (49/53) 93.5 (72/77)
2 100.0 (40/40) 97.4 (38/39) 91.7 (44/48) 88.4 (38/43) 90.0 (36/40) 90.2 (37/41)
3 83.0 (39/47) 95.7 (44/46) 84.1 (37/44) 86.1 (37/43) 92.0 (46/50) 85.3 (52/61)
4 94.3 (116/123) 90.8 (108/119) 69.0 (87/126) 92.6 (112/121) 91.7 (99/108) 89.2 (115/129)
5 88.9 (48/54) 88.9 (48/54) 85.2 (46/54) 90.0 (45/50) 85.4 (41/48) 98.7 (78/79)
6 100.0 (14/14) 92.9 (13/14) 83.3 (10/12) 84.6 (11/13) 100.0 (13/13) 87.5 (14/16)
7 90.0 (27/30) 93.1 (27/29) 83.9 (26/31) 93.6 (29/31) 84.4 (27/32) 100.0 (40/40)
8 90.9 (20/22) 90.0 (18/20) 67.9 (19/28) 87.5 (21/24) 83.3 (20/24) 92.0 (23/25)
9 100.0 (5/5) 100.0 (5/5) 60.0 (3/5) 75.0 (3/4) 83.3 (5/6) 83.3 (15/18)
10 86.4 (19/22) 82.6 (19/23) 80.0 (20/25) 96.5 (28/29) 90.0 (27/30) 94.7 (36/38)
11 92.1 (35/38) 100.0 (39/39) 82.1 (32/39) 94.6 (35/37) 89.5 (34/38) 88.2 (30/34)
12* 92.1 (35/38) 91.9 (34/37) 83.3 (30/36) 85.3 (29/34) - - - -
13 91.7 (22/24) 95.5 (21/22) 66.7 (16/24) 83.3 (20/24) 85.7 (24/28) 83.3 (20/24)
14 100.0 (21/21) 90.5 (19/21) 90.0 (18/20) 100.0 (20/20) 81.8 (18/22) 83.3 (10/12)
Study Area 91.0 (486/534) 92.1 (488/530) 79.7 (440/552) 89.5 (476/532) 89.2 (439/492) 91.3 (542/594)
*Village 12 withdrew after 17 months.
doi:10.1371/journal.pntd.0000835.t003
Table 4. Prevalence of follicular trachoma (TF) in children aged 1 to 9 years by village.
Village Baseline 2 months 6 months 12 months 17 months 30 months 60 months
%%%%% % %
1 39.2 (20/51) 40.0 (18/45) 23.6 (13/55) 15.4 (8/52) 14.6 (7/48) 10.2 (5/49) 25.0 (18/72)
2 5.4 (2/37) 5.0 (2/40) 0.0 (0/38) 0.0 (0/44) 0.0 (0/38) 5.6 (2/36) 8.1 (3/37)
3 35.6 (16/45) 33.3 (13/39) 38.6 (17/44) 32.4 (12/37) 21.6 (8/37) 8.7 (4/46) 3.9 (2/52)
4 9.8 (11/112) 6.0 (7/116) 4.6 (5/108) 3.4 (3/87) 8.0 (9/112) 0.0 (0/99) 6.1 (7/115)
5 10.6 (5/47) 12.5 (6/48) 6.3 (3/48) 6.5 (3/46) 0.0 (0/45) 4.9 (2/41 6.4 (5/78)
6 46.2 (6/13) 7.1 (1/14) 7.7 (1/13) 0.0 (0/10) 0.0 (0/11) 0.0 (0/13) 0.0 (0/14)
7 0.0 (0/31) 0.0 (0/27) 3.7 (1/27) 3.8 (1/26) 3.4 (1/29) 0.0 (0/27) 0.0 (0/40)
8 9.1 (2/22) 10.0 (2/20) 5.6 (1/18) 5.3 (1/19) 4.8 (1/21) 5.0 (1/20) 13.0 (3/23)
9 0.0 (0/5) 0.0 (0/5) 0.0 (0/5) 0.0 (0/3) 0.0 (0/3) 0.0 (0/5) 0.0 (0/15)
10 0.0 (0/21) 5.3 (1/19) 10.5 (2/19) 0.0 (0/20) 0.0 (0/28) 0.0 (0/27) 0.0 (0/36)
11 11.8 (4/34) 2.9 (1/35) 2.6 (1/39) 0.0 (0/32) 0.0 (0/35) 0.0 (0/34) 0.0 (0/30)
12* 31.4 (11/35) 14.3 (5/35) 5.9 (2/34) 0.0 (0/30) 13.8 (4/29) - - - -
13 0.0 (0/20) 4.5 (1/22) 0.0 (0/21) 6.3 (1/16) 5.0 (1/20) 0.0 (0/24) 0.0 (0/20)
14 15.8 (3/19) 14.3 (3/21) 21.1 (4/19) 5.6 (1/18) 5.0 (1/20) 0.0 (0/18) 0.0 (0/10)
Village Level
Mean (95% CI) 15.4 (6.1–24.6) 11.1 (4.3–17.9) 9.2 (2.9–15.7) 5.6 (3.9–13.7) 5.4 (1.5–9.4) 2.6 (0.4–4.9) 4.8 (0.4–9.3)
*Village 12 withdrew after 17 months.
doi:10.1371/journal.pntd.0000835.t004
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In this study a single round of mass antibiotic treatment was
given to a cluster of 14 Gambian villages with low prevalence
trachoma (TF%1–9 15.4%). In addition, the other components of
the SAFE strategy were promoted: free surgery was offered for
trichiasis, some limited health education on trachoma was
provided and latrines were installed at 18 months. The
government had previously improved the water supply. Prior to
treatment there were marked variations in village-level prevalence
of disease and infection, despite their close proximity and
environmental similarity. Six villages had cases of infection before
treatment. The initial response to treatment was heterogeneous. In
four villages with pre-treatment infections, no infection was
detected at 2-months, seven villages had no infection at baseline
or at 2-months and one village which had no baseline infection
had a single new case at 2-months. In these 12 villages only a few
isolated cases were subsequently detected during the five years of
follow-up. In the other two villages there appeared to be a failure
to respond to treatment [9]. This was attributed to possible re-
infection, because it was associated with en masse travelling to a
large religious festival in Senegal. Thereafter, the prevalence of
infection in these two villages gradually declined in the absence of
any additional antibiotic treatment for trachoma, reaching zero by
five years. In the absence of additional antibiotic treatment, this
decline is likely to be attributable to favourable environmental
factors. It is interesting to note that there was less Ct strain diversity
two-months after the mass treatment, which may have also
contributed to the decline in infection [16]. Overall, these
observations suggest that: (1) a single MDA was effective in most
of the study area, although re-infection seemed to have occurred in
two village; (2) the environmental conditions and/or the
susceptibility of the population did not favour the transmission
of C. trachomatis, leading to its decline and failure to re-emerge.
These findings contrast those from highly endemic regions such
as Ethiopia where C. trachomatis infection is not easily controlled or
readily re-emerges. For example, a study of a single MDA to eight
Ethiopian villages documented an initially good response to
treatment, but subsequently, several villages experienced re-
emergent infection [17]. Even where MDA was given every six
months for two years and the village prevalence of infection
dropped to very low levels or zero, re-emergence of infection was
reported two years after treatment stopped [18]. However, even in
these highly endemic parts of Ethiopia local elimination may be
possible with more prolonged treatment [19].
The Gambia is currently considered to have low levels of
endemic trachoma, although individual districts have TF%1–9
above the threshold for MDA [20]. Historically the levels were
Figure 1. The prevalence of TF in children aged 1 to 9 years for the 14 villages*. Individual villages are represented by the grey lines.
Several villages overlie each other with a prevalence of 0%. The overall village level average is represented by the black line. The dashed line
represents the WHO TF%1–9 treatment initiation threshold level of 10%. *Village No. 12 withdrew after 17-months. TF=Trachomatous Inflammation,
Follicular.
doi:10.1371/journal.pntd.0000835.g001
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during recent decades [4,21]. This reduction has been largely in
the absence of a MDA programme. The Gambia became a
beneficiary of the azithromycin donation programme through the
International Trachoma Initiative in 2007. Prior to this,
tetracycline eye ointment was used to opportunistically treat
individuals with active disease and their families. Therefore, it
seems more likely that the decline in the prevalence of trachoma is
mainly due to other factors.
Various environmental factors may favour this change.
However, it is difficult to determine their relative contributions.
All households in the study area had access to clean water within a
few minutes’ walk. Access to water improved markedly throughout
The Gambia during the 1990’s through the provision of covered
wells with hand-pumps by the government and coincided with a
general reduction in trachoma [4]. A similar transition was
observed in Malawi, which also coincided with marked improve-
ments in water supply and hygiene programme [22]. Easier access
to water combined with hygiene promotion probably leads to
improved facial cleanliness and washing of bed linen and clothes.
Numerous cross-sectional studies have found an association
between active trachoma and unclean faces [23,24]. This led to
the hypothesis that improving facial cleanliness may help to
control trachoma by suppressing transmission of C. trachomatis in
ocular secretions. However, the causality in this relationship could
go both ways, as active conjunctival inflammation can produce
secretions. This question was assessed in a trial of promoting facial
cleanliness, which found a reduction in severe trachoma (TI) but
not ‘‘any trachoma’’ (TF and/or TI) [25]. In our study we
observed a marked reduction in the prevalence of unclean faces as
the prevalence of TF%1–9 declined. We do not know whether this
promoted or was secondary to the decline in active trachoma or
whether it was related to health education about facial cleanliness.
Eye seeking flies (principally Musca sorbens)a r et h o u g h tt o
contribute to the transmission of C. trachomatis in The Gambia.
Measures to suppress the fly population by insecticide spraying
have been associated with a drop in the prevalence of active
trachoma [26,27]. As this fly preferentially breeds in exposed
human faeces, the construction and use of pit latrines may
indirectly reduce the transmission of infection [28]. However, in
a cluster randomised trial from the Gambia the provision of pit
latrines was only associated with a non-significant reduction in
the prevalence of active trachoma [27]. In our study latrine
coverage improved from 43% at baseline to 69% at five years. At
the same time fly-eye contacts dropped significantly. However,
we do not know whether this was due to a reduction in the
overall fly population secondary to the latrines or a reduction in
unclean faces, which attract flies. Whatever the explanation,
reducing the frequency of fly-eye contact probably reduces the
probability that C. trachomatis (if present) will be transmitted by
this route in this particular environment. In contrast, in a study
from Tanzania, intensive insecticide spraying was not associated
with a reduction in trachoma [29]. This may reflect differences
in the transmission ecology of this infection in different
regions.
The study population did not have ready access to antibiotics
with anti-chlamydial activity. Antibiotic use was monitored during
the first 17 months of the study, and we have no reason to think
that it was different during the rest of the follow-up period.
Background antibiotic use probably contributed little to the
decline in C. trachomatis, in contrast to a study from Nepal, where
a much higher background use of antibiotics may have
contributed to a decline in trachoma [30].
During our study there were no significant demographic
changes, such as fewer young children, favouring trachoma
control. The relatively small village size in this part of The
Gambia may make trachoma less stable. In a smaller community
children probably come into contact with a smaller absolute
number of potentially infected people than in a larger village,
possibly reducing their chance of becoming infected.
Table 5. Prevalence of C.trachomatis infection* in children aged 1 to 9 years by village.
Village Baseline 2 months 6 months 12 months 17 months 30 months 60 months
%%%%%% %
1 5.9 (3/51) 20.0 (9/45) 20.0 (11/55) 11.5 (6/52) 16.7 (8/48) 4.1 (2/49) 0.0 (0/72)
2 0.0 (0/37) 2.5 (1/40) 2.6 (1/38) 9.1 (4/44) 2.6 (1/38) 5.6 (2/36) 0.0 (0/37)
3 53.3 (24/45) 59.0 (23/39) 25.0 (11/44) 35.1 (13/37) 29.7 (11/37) 0.0 (0/46) 0.0 (0/52)
4 5.4 (6/112) 0.0 (0/116) 0.0 (0/108) 0.0 (0/87) 0.0 (0/112) 3.0 (3/99) 1.7 (2/115)
5 0.0 (0/47) 0.0 (0/48) 0.0 (0/48) 0.0 (0/46) 0.0 (0/45) 0.0 (0/41 1.3 (1/78)
6 15.4 (2/13) 0.0 (0/14) 0.0 (0/13) 0.0 (0/10) 0.0 (0/11) 0.0 (0/13) 0.0 (0/14)
7 3.2 (1/31) 0.0 (0/27) 0.0 (0/27) 0.0 (0/26) 0.0 (0/29) 0.0 (0/27) 0.0 (0/40)
8 0.0 (0/22) 0.0 (0/20) 0.0 (0/18) 0.0 (0/19) 0.0 (0/21) 0.0 (0/20) 0.0 (0/23)
9 0.0 (0/5) 0.0 (0/5) 0.0 (0/5) 0.0 (0/3) 0.0 (0/3) 0.0 (0/5) 0.0 (0/15)
10 0.0 (0/21) 0.0 (0/19) 0.0 (0/19) 0.0 (0/20) 0.0 (0/28) 0.0 (0/27) 0.0 (0/36)
11 0.0 (0/34) 0.0 (0/35) 0.0 (0/39) 0.0 (0/32) 0.0 (0/35) 0.0 (0/34) 0.0 (0/30)
12{ 0.0 (0/35) 0.0 (0/35) 0.0 (0/34) 3.3 (1/30) 0.0 (0/29) - - - -
13 0.0 (0/20) 0.0 (0/22) 4.8 (1/21) 0.0 (0/16) 0.0 (0/20) 0.0 (0/24) 0.0 (0/20)
14 52.6 (10/19) 0.0 (0/21) 0.0 (0/19) 0.0 (0/18) 0.0 (0/20) 0.0 (0/18) 0.0 (0/10)
Village Level
Mean (95% CI) 9.7 (0.0–20.6) 5.8 (0.0–15.2) 3.7 (0.0–8.4) 4.2 (0.0–9.8) 3.5 (0.0–8.6) 1.0 (0.0–2.1) 0.2 (0.0–0.6)
*C. trachomatis infection detected by Amplicor.
{Village 12 withdrew after 17 months.
doi:10.1371/journal.pntd.0000835.t005
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prevalence of disease declines is the increasing uncertainty over the
infection status of formerly endemic communities, because of a
mismatch between disease signs and chlamydial infection [5]. We
have previously reported that prior to MDA in these villages a
minority of the people with C. trachomatis had TF and conversely
many with clinically active trachoma did not have infection [6,9].
At the five year follow-up two villages had a TF%1–9 of .10%,
triggering intervention with MDA, under current WHO guidelines
[8]. However, neither village had a single case of chlamydial
infection. These observations are consistent with those from a
survey conducted elsewhere in The Gambia in the same year
(2006) as our five year follow-up [20]. With the increasing
effectiveness of trachoma control programmes other countries are
likely to reach the low prevalence situation current in The
Gambia. The implication is that, applying the current intervention
algorithms, many uninfected communities will continue to receive
unnecessary rounds of MDA on multiple occasions. It remains
uncertain, on clinical grounds, when MDA can stop without re-
emergent infection.
The mismatch of disease and infection probably arises for
several reasons in low prevalence settings. Firstly, there is a
Figure 2. The prevalence of Chlamydia trachomatis infection* in children aged 1 to 9 years for the 14 villages
{. Individual villages are
represented by the grey lines. Several villages overlie each other with a prevalence of 0%. The overall village level average is represented by the black
line. *Chlamydia trachomatis infection determined by Amplicor CT PCR assay.
{Village No. 12 withdrew after 17-months.
doi:10.1371/journal.pntd.0000835.g002
Table 6. Chlamydia trachomatis infection load.
Baseline 2 months 6 months 12 months 17 months 30 months 60 months
Load (95%CI) Load (95%CI) Load (95%CI) Load (95%CI) Load (95%CI) Load (95%CI) Load (95%CI)
Individual* 169 (100–286) 186 (103–333) 879 (371–2083) 620 (229–1681) 400 (92–1742) 72 (14–371) 17 (5–59)
Community{ 0.44 (0.33–0.57) 0.34 (0.24–0.44) 0.24 (0.16–0.33) 0.20 (0.12–0.28) 0.14 (0.08–0.21) 0.07 (0.02–0.09) 0.02 (0.01–0.04)
*The individual infection load is the geometric mean and 95% CI of the C. trachomatis infection load expressed in copies of ompA/swab, for all infected individuals in the
study population.
{The community load of infection is the Williams Mean for the study population (including uninfected individuals), expressed in copies of the ompA/swab.
doi:10.1371/journal.pntd.0000835.t006
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and active disease [31,32]. There is probably an initial subclinical
‘‘incubation’’ period prior to the development of inflammatory
signs in the conjunctiva; subsequently the inflammatory signs can
linger for many weeks after the infection becomes undetectable. In
contrast, in high prevalence settings this asynchronous time course
is less evident, as the spacing between separate infection and
disease episodes is shorter and may indeed overlap, increasing the
correlation. Secondly, in low prevalence settings the disease is
probably milder, with some infected individuals having conjunc-
tival inflammatory signs, which do not reach the TF diagnostic
threshold. Thirdly, follicular conjunctivitis is not exclusively
caused by C. trachomatis. In low prevalence settings a greater
proportion of ‘‘TF’’ will be due to other agents, such as
adenovirus, causing outbreaks, which mimic endemic trachoma.
In a number of studies the prevalence of TF after the successful
control of C. trachomatis infection with MDA has taken several years
to decline [9,33,34,35]. The reason for this is not known, as most
clinical episodes last only for a few weeks; however, it is likely that
in many situations MDA will inevitably continue some time after
the infection has been successfully cleared from formerly endemic
communities. Finally, clinical observations and laboratory tests
may both produce false negative and false positive results.
The observation that incident TT developed after the
prevalence of C. trachomatis dropped is important. This indicates
the potential for cicatricial disease progression after the chlamydial
infection is controlled. The reasons for this are unknown, although
other pro-inflammatory stimuli such as non-chlamydial bacterial
infection and ocular dryness may contribute [36,37]. The
implication for control programmes is that surveillance and
treatment for TT will need to continue for some years after the
chlamydial infection has been successfully controlled.
This study has a number of limitations. Firstly, in the absence of
an untreated control group, it is not possible to determine what
proportion of the reduction seen in these villages was due to the
treatment at baseline and what was due to a secular trend.
However, it seems likely that both contributed to the decline.
Secondly, there was a long gap between the last two time-points. It
is unknown what occurred during that time. Thirdly, we do not
routinely run parallel assays for human nucleic acid in swab
samples to check specimen adequacy. However, in a separate
study using the same swab type collected in the same standardised
manner by the same ophthalmologist from subjects in this study
area we found that human RNA could be extracted from all swabs
collected [38]. Field control swabs were not collected, as this was
not standard practice at that time. Finally, one village withdrew
from the study after the first 17 months. At enrolment this village
had one of the higher rates of TF%1–9 and on the last occasion it
was assessed it had four cases of TF but no cases of infection. We
do not know what happened in this village subsequently and what
affect this might have had on the surrounding villages.
In summary, our findings suggest that a single round of mass
antibiotic treatment in association with the other components of
the SAFE strategy may be all that is required to clear C. trachomatis
infection in low prevalence settings, if reasonably high antibiotic
coverage is achieved. We also observed an unusual re-infection
episode soon after treatment, which was associated with travel.
However, the conditions were such that this infection did not
persist or appear to transfer to neighbouring villages, indicating
the critical importance of F&E interventions that suppress
transmission, in addition to antibiotic treatment. Coordinated
attempts to control trachoma across wide geographical areas may
also reduce the risk of re-infection. The current guidelines will
probably lead to widespread overtreatment of communities in
similar settings. This might be preventable if a role for suitable
field-based diagnostic tests for C. trachomatis can be established in
confirming elimination of infection. With the implementation of
the SAFE Strategy, many previously highly endemic regions will
eventually reach this position. Therefore, a clear evidence-based
approach for handling the trachoma ‘‘End Game’’ is still needed.
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